The Food and Drug Administration (FDA) has given the green light to two groundbreaking over-the-counter continuous glucose monitors (CGMs) developed by Abbott: Lingo and Libre Rio. These devices mark significant advancements in accessible glucose monitoring for both metabolic health enthusiasts and individuals managing type 2 diabetes without insulin.
Lingo, designed for individuals without diabetes seeking to enhance their overall health and wellbeing, offers continuous glucose monitoring capabilities without the need for a prescription. Positioned as a tool for improving metabolic health, Lingo provides personalized insights and coaching recommendations via a smartphone app, based on glucose data collected over a two-week period. By analyzing various lifestyle factors such as diet, physical activity, sleep, and stress, Lingo empowers users to make informed decisions to optimize their metabolic health in real time. Notably, Lingo has already been launched in the United Kingdom and is poised to revolutionize glucose monitoring practices upon its release in the United States.
Meanwhile, Libre Rio caters to adults with type 2 diabetes who manage their condition through lifestyle modifications rather than insulin therapy. Like its predecessor, FreeStyle Libre 2, Libre Rio boasts a compact design and a two-week lifespan, making it a convenient and user-friendly option for glucose monitoring. With the ability to measure blood glucose levels ranging from 40 to 400 mg/dL, Libre Rio provides valuable insights into blood sugar patterns, empowering individuals to proactively manage their diabetes through diet and physical activity.
Both Lingo and Libre Rio leverage Abbott’s FreeStyle Libre technology, offering consumers reliable and accurate glucose monitoring solutions in a familiar and accessible format. The FDA’s clearance of these over-the-counter CGMs represents a significant step towards democratizing glucose monitoring and empowering individuals to take control of their metabolic health and diabetes management without the need for medical intervention.
As anticipation mounts for the launch of Lingo and Libre Rio in the United States, details regarding pricing and availability are eagerly awaited. These innovative CGMs are poised to redefine the landscape of glucose monitoring, offering newfound autonomy and insight to individuals striving for better health outcomes.
Related topics:
What Is Worse Type One Or Type Two Diabetes
